Objective. To determine the clinical efficacy of sclerosing injections in patients with chronic low back pain.
Sclerosing injections have been used in patients with
in the Sansum Medical Clinic in Southern California chronic low back pain since the 1950s. They are advoc-(Ongley et al. [11] and Klein et al. [12] ). They included ated particularly in patients with clinical features of different amounts of manipulative therapy and local 'spinal instability' [1] [2] [3] [4] [5] . The rationale for their use is anaesthesia in treatment protocols for treatment and based on two premises. First, that the laxity of the control groups. The results are therefore difficult to ligaments and fascia supporting the lumbar motion interpret. segments is responsible for many cases of chronic low A number of adverse events including paralysis and back pain [6 ] and second, that the injection of substances death were reported with the use of early proliferative which initiate an inflammatory response will strengthen agents such as psyllium seed oil and zinc sulphate [13] [14] [15] . these ligaments and consequently reduce back pain These events occurred following inadvertent intrathecal [7, 8] .
injection. The most commonly used solution amongst There are a number of reports suggesting that scleroscurrent practitioners is a mixture of glucose, glycerine ing injections are a safe and effective treatment for low and phenol which has been demonstrated to be safe. back pain [9, 10] midazolam. In order reliably to detect a 50% or greater difference Baseline results were compared using Mann-Whitney in reported pain or disability between the placebo and and t-tests. Mean scores for the questionnaire results active group as seen in the previous studies ( b = 90%, and lumbar flexion for the measurements at baseline, 1, a = 0.05) a total of 34 patients in each group was needed.
3 and 6 months were compared using one-way analysis The inclusion criteria included males and females aged of variance (ANOVA). 18-71 yr with mechanical low back pain of more than 6 months' duration. Patients were excluded if they were pregnant or contemplating pregnancy, had evidence of Results nerve root entrapment, unresolved litigation, severe Seventy-four patients were recruited and there were no co-existing disease or body weight greater than 20 kg drop-outs over the study period. There were no statisticover their ideal. ally significant differences between the placebo and Patients were randomly allocated (random number treatment groups at baseline ( Table 1 ). All patients list) to placebo or active treatment.
receiving compensation had had their claims settled. The study had local Ethics Committee approval. Figure 1 shows the mean and standard errors for the Assessment methods short-form McGill Pain Questionnaire ( VAS, total word scores and present pain intensity) and the pain drawing Subjects were asked to complete a screening questiongrid by Margolis. There was a trend downwards in both naire that combined demographic characteristics with groups over the study period, but this did not reach information about previous and present history and statistical significance. Figure 2 shows the mean and current medication and completed the following specific standard errors for the MSPQ scores, the Zung outcome tools: the short-form McGill Pain Depression Inventory, the Oswestry Disability Questionnaire [16 ] normal saline solution combined with 5 ml of 1% by an experienced operator [11] . A rigid 3◊ × 20G, Back surgery 11% 11%
3◊ × 22G or occasionally 3.5◊ × 20G needle was used.
Receiving benefits 32% 39% Currently employed 50% 52%
All injections were made from a single insertion into the Current smoker 34% 33%
following sites: tip of the spinous process of L4 and L5
Other treatments 8% 11%
and associated supraspinous and interspinous ligaments;
Taking analgesics 63% 67%
apophyseal joint capsules at L4-5 and L5-S1; attach- Patients with symptoms of longer than 10 yr were underwent infiltration of lignocaine into specific sites followed by spinal manipulation and injection of triamcisignificantly older and heavier than those with a shorter nolone into the gluteus medius origin. In the Klein study history, but there were no significant differences between both placebo and treatment groups received the same placebo and treatment groups for any measurement protocol but the placebo group in the Ongley study parameter when analysed according to age group (<5 yr, received a smaller dose of lignocaine (10 ml of 0.5% 5-10 yr or >10 yr). compared with 60 ml 0.5%) and a sham manipulation. There were no significant differences in the results In both studies there followed six weekly ligament when analysed without the patients who were receiving injections of either sclerosant mixture or placebo accordcompensation. ing to the protocol described previously. All patients A few subjects reported a transient increase in back were taught flexion and extension exercises and were pain following the injections, but there were no differencouraged to continue at subsequent visits. In both ences between the treatment and control groups and no studies there were significant improvements in both other significant adverse reactions.
treatment and placebo groups. The magnitude of the improvement was greater in the Ongley study which Discussion made a comparison of the complete regimen than in the Klein study where both treatment and placebo groups Our findings suggesting that sclerosing injections are of received manipulation, corticosteroid injections and no greater benefit than placebo in the treatment of exercises. While comparison is difficult the differences patients with chronic low back pain appear at odds with in results suggest that the complete regimen is more the studies of Ongley and Klein and the clinical experieffective than the component parts. While we have been ence of many physicians both in Europe and North unable to demonstrate improvement with sclerosant America [22] .
injections alone, their combination with manipulation, The reasons for this discrepancy may be related to corticosteroids and exercise appears to be beneficial. patient selection (see [11, p. 37] ), radiological, racial or Furthermore, it may be that six weekly injections are social differences between the trial centres, technical required before a benefit can be demonstrated. differences in the treatment programmes, or insensitivity
We aimed to use similar outcome measures to the of the assessments.
Californian studies in order to allow reasonable comOur patients represent a heterogeneous population parison. They evaluated pain using an 8 cm VAS scale, with undifferentiated chronic low back pain. They were the pain drawing grid of Margolis and the disability not specifically identified as likely to benefit from sclerosquestionnaire of Roland and Morris [23] . Both the ing therapy, for example clinical features of 'spinal latter and the Oswestry Disability Questionnaire are instability' were not sought (defined clinically as episodic validated tools of self-reported disability in patients with severe exacerbations of pain and muscle spasm following back pain and have been used and evaluated more minor movement). Many patients were not considered frequently than other scales [24] . Thus, it seems unlikely ideal candidates for sclerosing injections by the operator that differences in outcome assessments could explain at the time of the treatment for a variety of reasons the differences between the three trials. relating to technical difficulties, deconditioning, patients Finally, the power of our study was calculated to not relying on invalidity benefit, excessive psychological miss a 50% difference between placebo and treatment stress, etc. even though they technically fulfilled the groups with confidence. It is possible that we have inclusion criteria. Therefore, the group of patients missed a smaller improvement that would be clinically recruited into our study was likely to respond poorly to significant. We chose the 50% level because of the large any single intervention in keeping with the relatively placebo response seen in the other studies. poor prognosis in the group of patients in the UK In summary, following three, weekly sclerosant injectoday. These factors may also account for the surprising tions to the lumbar spinal ligaments we have been lack of a significant placebo effect in our study compared unable to demonstrate improvement in pain, selfwith the Californian trials. These patients may be better reported function, somatization, depression or spinal suited to functional restoration or pain management flexion in patients with undifferentiated chronic back programmes.
pain. The results might be explained in terms of differThe patients in the Californian studies showed a ences in patient selection, underlying pathology, social spectrum of radiological and imaging disorders characcircumstances, additional treatment modalities or teristic of the heterogeneous nature of patients with insufficient power of the study. Further research is chronic mechanical back pain. We have not assessed needed to identify which components of the regimens these parameters in our subjects and it is possible that are most effective and whether there are subgroups of differences exist. Furthermore, there are likely to be patients who are more likely to respond to these safe racial, social and geographical differences between treatments. Southern California and Dorset that might influence the response to the interventions.
